Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

NRX Pharmaceuticals (NRXP) EBIAT (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed EBIAT for 2 consecutive years, with $360000.0 as the latest value for Q4 2025.

  • Quarterly EBIAT rose 103.97% to $360000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.6 million through Dec 2025, down 13.92% year-over-year, with the annual reading at -$28.6 million for FY2025, 13.91% down from the prior year.
  • EBIAT for Q4 2025 was $360000.0 at NRX Pharmaceuticals, up from -$5.9 million in the prior quarter.
  • The five-year high for EBIAT was $360000.0 in Q4 2025, with the low at -$17.6 million in Q2 2025.